---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-085894"
form_type: "8-K"
ticker: "REPL"
cik: "0001737953"
company_name: "Replimune Group, Inc."
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T04:19:08.844454+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Replimune Q1 net loss $42.3M; CERPASS trial hits 180-patient enrollment target

## Summary
- Cash & short-term investments $395.1M as of June 30, 2022, vs $395.7M at March 31, 2022.
- Net loss $42.3M for Q1 ended June 30, 2022, up from $27.3M year-over-year; R&D expenses rose to $29.5M.
- CERPASS registration trial for RP1 in CSCC reached target enrollment of 180 patients; primary data expected H1 2023.
- First 75 patients enrolled in IGNYTE anti-PD1 failed melanoma cohort; data snapshot with 6-month follow-up expected Q4 2022.
- Phase 2 development program for RP2/3 in SCCHN, HCC, and CRC expected to initiate Q1 2023.

## SEC filing metadata
- accession: 0001104659-22-085894
- form_type: 8-K
- ticker: REPL
- cik: 0001737953
- company_name: Replimune Group, Inc.
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737953/000110465922085894/0001104659-22-085894-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737953/000110465922085894/tm2222536d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-085894
- JSON: https://secwatch.observer/filing/0001104659-22-085894.json
- Plain text: https://secwatch.observer/filing/0001104659-22-085894.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.